Abstract
Brain metastases in malignant melanoma carries a poor prognosis with minimal response to any therapy. The purpose of this pilot analysis was to find the effectiveness of vemurafenib, an oral BRAF inhibitor, and radiation therapy in V600 mutated melanoma with brain metastases. BRAF mutation status of the melanoma patients was determined by real-time PCR assay. Retrospective analysis was performed on twelve patients who had the mutation and were treated with either stereotactic radiosurgery or whole brain radiation therapy prior to or along with vemurafenib at a dose of 960 mg orally twice a day. Clinical and radiological responses, development of new brain metastases, overall survival and toxicity were assessed. Improvement in neurological symptoms was seen in 7/11 (64 %) following therapy. Radiographic responses were noted in 36/48 (75 %) of index lesions with 23 (48 %) complete responses and 13 (27 %) partial responses. Six month local control, freedom from new brain metastases and overall survival were 75, 57 and 92 %. Four patients had intra-tumoral bleed prior to therapy and two patients developed steroid dependence. One patient experienced radiation necrosis. This retrospective study suggests that melanoma patients with brain metastases harboring BRAF mutation appear to be a distinct sub-group with a favorable response to vemurafenib and radiation therapy and acceptable morbidity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Staudt M et al (2010) Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer 102(8):1213–1218
Fife KM et al (2004) Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 22(7):1293–1300
Selek U et al (2004) Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. Int J Radiat Oncol Biol Phys 59(4):1097–1106
Soffietti R, Ruda R, Trevisan E (2008) Brain metastases: current management and new developments. Curr Opin Oncol 20(6):676–684
Gonzalez-martinez J et al (2002) Gamma knife radiosurgery for intracranial metastatic melanoma: a 6-year experience. J Neurosurg 97(supplement 5):494–498
Hwu W-J et al (2005) Temozolomide plus thalidomide in patients with brain metastases from melanoma. Cancer 103(12):2590–2597
Davies H et al (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949–954
Curtin JA et al (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353(20):2135–2147
Long GV et al (2012) Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13(11):1087–1095
Falchook GS et al (2012) Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379(9829):1893–1901
Bollag G et al (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467(7315):596–599
Chapman PB et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507–2516
Sosman JA et al (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366(8):707–714
Rochet NM et al (2012) Melanoma brain metastases and vemurafenib: need for further investigation. Mayo Clin Proc 87(10):976–981
Soffietti R, Trevisan E, Ruda R (2012) Targeted therapy in brain metastasis. Curr Opin Oncol 24(6):679–686
Mittapalli RK et al (2012) Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032). J Pharmacol Exp Ther 342(1):33–40
Gerstner ER, Fine RL (2007) Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol 25(16):2306–2312
Agarwala SS et al (2004) Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 22(11):2101–2107
Atkins MB et al (2008) Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. Cancer 113(8):2139–2145
Hwu WJ et al (2005) Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer 103(12):2590–2597
Avril MF et al (2004) Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 22(6):1118–1125
Margolin K et al (2012) Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 13(5):459–465
Rochet NM, Kottschade LA, Markovic SN (2011) Vemurafenib for melanoma metastases to the brain. N Engl J Med 365(25):2439–2441
Sambade MJ et al (2011) Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. Radiother Oncol 98(3):394–399
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Narayana, A., Mathew, M., Tam, M. et al. Vemurafenib and radiation therapy in melanoma brain metastases. J Neurooncol 113, 411–416 (2013). https://doi.org/10.1007/s11060-013-1127-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-013-1127-1